open access

Ahead of print
Clinical vignette
Submitted: 2022-05-10
Accepted: 2022-05-28
Published online: 2022-08-04
Get Citation

Double transformation of relapsing juvenile myelomonocytic leukemia to refractory acute myeloid leukemia

Tomasz Styczyński1, Jagoda Sadlok1, Monika Richert-Przygońska2, Robert Dębski2, Małgorzata Kubicka2, Beata Kuryło-Rafińska2, Krzysztof Czyżewski2
DOI: 10.5603/AHP.a2022.0038
Affiliations
  1. Student Scientific Society, Collegium Medicum, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland
  2. Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University in Toruń, Jurasz University Hospital 1, Bydgoszcz, Poland

open access

Ahead of print
CLINICAL VIGNETTE
Submitted: 2022-05-10
Accepted: 2022-05-28
Published online: 2022-08-04

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

juvenile myelomonocytic leukemia, acute myeloid leukemia, transformation; relapse

Supp./Additional Files (1)
First page
Download
21KB
About this article
Title

Double transformation of relapsing juvenile myelomonocytic leukemia to refractory acute myeloid leukemia

Journal

Acta Haematologica Polonica

Issue

Ahead of print

Article type

Clinical vignette

Published online

2022-08-04

Page views

14

Article views/downloads

5

DOI

10.5603/AHP.a2022.0038

Keywords

juvenile myelomonocytic leukemia
acute myeloid leukemia
transformation
relapse

Authors

Tomasz Styczyński
Jagoda Sadlok
Monika Richert-Przygońska
Robert Dębski
Małgorzata Kubicka
Beata Kuryło-Rafińska
Krzysztof Czyżewski

References (7)
  1. Lasho T, Patnaik MM. Juvenile myelomonocytic leukemia — a bona fide RASopathy syndrome. Best Pract Res Clin Haematol. 2020; 33(2): 101171.
  2. Mayerhofer C, Niemeyer C, Flotho C. Current treatment of juvenile myelomonocytic lLeukemia. J Clin Med. 2021; 10(14): 3084.
  3. Gupta AK, Meena JP, Chopra A, et al. Juvenile myelomonocytic leukemia — a comprehensive review and recent advances in management. Am J Blood Res. 2021; 11(1): 1–21.
  4. Niemeyer CM. JMML genomics and decisions. Hematology Am Soc Hematol Educ Program. 2018; 2018(1): 307–312.
  5. Niemeyer CM, Flotho C. Juvenile myelomonocytic leukemia: who's the driver at the wheel? Blood. 2019; 133(10): 1060–1070.
  6. Chen S, Li F, Xu D, et al. The function of RAS mutation in cancer and advances in its drug research. Curr Pharm Des. 2019; 25(10): 1105–1114.
  7. Schönung M, Meyer J, Nöllke P, et al. International consensus definition of DNA methylation subgroups in juvenile myelomonocytic leukemia. Clin Cancer Res. 2021; 27(1): 158–168.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl